TransEnterix Enters Next Phase of Development of SurgiBot System
TransEnterix, Inc., a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that multiple surgeons have used SurgiBot, the company’s patient-side minimally invasive robotic system, to successfully complete general surgery procedures in the porcine model. The procedures performed in the pre-clinical testing included cholecystectomy and sleeve gastrectomy.
Dr. Michel Gagner, who is president of the 2014 World Congress of the International Federation for the Surgery of Obesity & Metabolic Disorders, is among the surgeons participating in the pre-clinical testing.
“SurgiBot has promise as a patient-side robotic system for precise dissection during many types of surgical procedures,” Gagner said. “As an experienced laparoscopic surgeon, I appreciate the benefits of robotic precision, strength and ergonomics while remaining in control of the operative site in the sterile field. The system also allows the surgeon to control multiple instruments and a camera and therefore reduce reliance on other assistants during procedures.” “We’re pleased to have achieved this important milestone in the development of SurgiBot,” said Todd M. Pope, president and CEO of TransEnterix. “We are committed to executing our plan of delivering a revolutionary patient-side robotic system to benefit patients, surgeons and hospitals.” The company plans to submit a 510(k) application for clearance with the U.S. Food and Drug Administration for the SurgiBot system later in 2014.